. AC98-6446 demonstrated bactericidal activity in terms of the reduction in the viable counts (>3 log 10 CFU/ml) of staphylococcal and streptococcal isolates and a marked decrease in the viable counts of most enterococcal strains (from 0.2 to 2.5 log 10 CFU/ml). Unlike vancomycin, which demonstrates time-dependent killing, AC98-6446 demonstrated concentration-dependent killing. The potent activity, novel structure, and bactericidal activity demonstrated by AC98-6446 make it an attractive candidate for further development.

The Discovery of RFI-641 as a Potent and Selective Inhibitor of the Respiratory Syncytial Virus.-The title compound (Ia) emerged from the analysis of the structure-activity relationship in a series of biphenyl triazine anionic compounds possessing specific anti-RSV activity. -(NIKITENKO, ANTONIA A.; RAIFELD, YURI E.; WANG, T